<DOC>
	<DOCNO>NCT01410526</DOCNO>
	<brief_summary>Protocol Synopsis Protocol title : Assessment peritoneal immune response patient severe intra-abdominal sepsis manage laparostomy VAC Purpose : Assessment peritoneal immune response patient severe intra-abdominal sepsis Design : Prospective , single-center study Patient Population : Male female adult ( &gt; 18 year ) severe intra-abdominal sepsis No . Subjects : 60 patient divide two group , 30 patient severe intra-operative sepsis 30 patient without sepsis schedule undergo major abdominal operation ( middle line incision &gt; 15cm ) . The study estimate 2 year enroll Duration Follow-up : Follow-up perform daily hospitalize , patient discharge decease . Endpoints : 1 . To measure peritoneal cytokine level patient severe intra-abdominal sepsis . 2 . To correlate cytokine level abdominal cavity serum plasma . 3 . To correlate cytokine response serum plasma peritoneal fluid mortality morbidity . 4 . To compare cytokine result serum plasma peritoneal fluid patient severe intra-abdominal sepsis patient undergo major laparotomy without sepsis . 5 . To assess microbial load abdominal cavity patient severe sepsis . 6 . To assess biofilm formation VAC polyurethane sponge .</brief_summary>
	<brief_title>Assessment Peritoneal Immune Response Patients With Severe Intra-abdominal Sepsis Managed With Laparostomy Vacuum Assisted Closure ( VAC )</brief_title>
	<detailed_description>Principal Investigator Statement : ……………………………………………… 1 Protocol Synopsis : ……………………………………………………………… 2 Table Content : ……………………………………………………………… . .4 1.0 Introduction : …………………………………………………………… . 5 2.0 Techniques description : ……………………………..………………… 6 3.0 Objectives : ……………………………..…………………………………7 4.0 Design study population : …………………………………………… 7 5.0 Study procedure : ……………………………..………………………… 8 6.0 Complications adverse event : …………………………………… 15 7.0 Statistical analysis : ……………………………..……………………… 15 8.0 Data monitoring plan : ……………………………..………………… 16 9.0 Data confidentiality : ……………………………..…………………… 16 10.0 Funding : ……………………………..………………………………… 16 11.0 Ethics : ……………………………..…………………………………… 16 12.0 Informed consent : ……….……………………………..……………… . 17 13.0 References : ……………………………………..……………………… 18 1.0 INTRODUCTION Severe abdominal sepsis define sepsis plus organ dysfunction cause condition derive peritoneal cavity [ 1 ] . The essential management patient severe sepsis remain unchanged divide broadly sepsis control , antimicrobial therapy hemodynamic stabilization [ 2 ] . Infection control mainly involve surgical exploration temporary permanent resolution septic agent [ 3 ] . Open abdomen treatment remain one valid approach patient severe abdominal sepsis [ 4 ] . Open abdomen management mandate avoid abdominal compartment syndrome , case inability re-approximate abdominal fascia regardless viscera oedema intra-abdominal pressure case unclear inadequate source control [ 5 ] . Topical negative pressure abdominal vacuum-assisted closure ( VAC ) device introduce , provide new option manage open abdomen [ 6-8 ] . Cytokines group proteins produce variety cell play active role immune system . Sepsis syndrome seem result overwhelm systemic inflammation cause excessive release cytokine systemic circulation [ 9 ] . During last decade many clinical study assess cytokine concentration serum plasma patient SIRS sepsis [ 10-13 ] . Despite board study analysis cytokine response serum plasma , literature poor peritoneum immune response intra-abdominal sepsis [ 14-15 ] , whereas majority study concerned patient elective surgery [ 16-18 ] . This protocol design assess cytokine level peritoneal cavity severe intra-abdominal sepsis compare level correspond value serum plasma . Additionally , cytokine value serum plasma peritoneum compare patient without sepsis underwent major elective laparotomy ( middle line incision &gt; 15cm ) . Moreover , cytokine level correlate morbidity mortality . 2.0 STUDY PROTOCOL In patient origin sepsis confirm pre-operative abdominal , laparotomy require . After incision confirmation intra-abdominal sepsis , involve whole peritoneal cavity , peritoneal fluid sample microbiology culture cytokine assessment . The appropriate source control intervention make peritoneal lavage perform use sterile isotonic sodium chloride solution . At end operation decision open abdomen make surgeon , base severity sepsis . If laparostomy decide , temporary abdominal closure perform Vacuum Assisted Closure ( VAC ) system plus dynamic suture [ 19 ] . After two-day application VAC , previous exist dress remove . Peritoneal fluid sample blood sample obtain cytokine assessment . The abdominal cavity carefully rinse saline solution various abdominal space inspect collection . Additionally , peritoneal fluid sample obtained culture quantitive analysis . Sequentially , VAC dress application perform base previously describe protocol [ 19 ] . Patients return operate room sequential fascial closure replacement sponge suture every 2 day final open abdomen closure . Peritoneal fluid blood serum sample obtain every VAC change permanent abdominal closure patient 's decease . A piece polyurethane sponge VAC system send microbiology department detection biofilm formation . 3.0 OBJECTIVES 1 . To assess cytokine peritoneal fluid patient severe intra-abdominal sepsis . 2 . To compare serum plasma cytokine value patient severe intra-abdominal sepsis correspond value peritoneal fluid . 3 . To compare cytokine value serum plasma peritoneal fluid patient severe intra-abdominal sepsis patient without sepsis underwent major elective laparotomy . 4 . To evaluate parameter influence successful , primary abdominal closure , morbidity mortality . 5 . To assess microbial load abdominal cavity patient severe sepsis . 6 . To assess biofilm formation VAC polyurethane sponge . 4.0 DESIGN AND STUDY POPULATION The study design prospective single center study . Any patient sepsis suspect pre-operative abdominal origin need laparotomy postoperative laparostomy assess . Control group constitute patient without sepsis underwent major elective laparotomy . 4.1 Inclusion Criteria 1 . Patient &gt; 18 year old 2 . 30 patient severe abdominal sepsis order form study group 30 patient without sepsis undergo major elective surgery ( middle line incision &gt; 15cm ) form control group . 3 . Patient relatives sign date write informed consent form ( ICF ) indicate understand study procedure 4.2 Exclusion Criteria 1 . Patient 's Manheim Peritonitis Score &lt; 29 2 . Patient 's pre-operative SOFA score &lt; 6 3 . The use temporary abdominal closure system 4 . Decease first VAC dress change 5 . Patient participate another clinical trial may affect study 's outcome 6 . Patients immune deficiency 7 . Documented seropositivity human immunodeficiency virus ( AIDS ) 8 . Patient receive steroid treatment medical condition 9 . Patient receive chronic anti-inflammatory treatment 10 . Patient receive anti- TNF treatment 11 . Pre-existing parechymal liver disease ( Cirrhosis - Child-Pugh C ) 12 . Pregnancy 4.3 Duration study The study conduct 30 patient group treat . It estimate take 2 year enroll patient . 5.0 STUDY GROUP PROCEDURES 5.1 Pre-Surgery The following pre-surgery information record : 1 . Demographic information include : Date birth ( age ) , gender , ethnicity 2 . Pre-operative duration sepsis - symptom 3 . Co-morbidities 4 . BMI 5 . ASA score 6 . SOFA score 7 . APACHEII score 8 . Intra-abdominal pressure ( IAP ) 9 . Preoperative lab ( WBC , Ht , Hb , SGOT , SGPT , LDH , Glu , Ure , Cre , K+ , Na+ , Ca2+ , Mg++ , TP , Alb , ALP , γ-GT , Amylase ) 10 . Coagulation ( Fibrinogen , PT , aPTT , INR ) 11 . CRP , PCT , Lectin Binding Protein ( LBP ) 12 . Ischemia Modulated Albumine ( IMA ) 13 . Pre-operative Diagnosis 14 . Medications 15 . Current past history surgical medical comorbidities 16 . Measurement blood serum plasma sample : IL 1α , IL 1β , IL6 , IL8 , IL12 , IL 10 , IL 18 , INF-γ , TNF-α , PGF-B , PAF , FGF-β , C5q , C3q , ICAM-I ( CD54 ) . 17 . Measurement blood serum plasma sample : fractalkine , CCL6 . 5.2 Intra-operative The surgeon perform laparotomy intra-operative sepsis source control . Peritoneal fluid sample obtained culture . Assessment intra-peritoneal sepsis perform decision open abdomen management make . At end surgery , peritoneal blood sample obtain cytokine measurement . The following intraoperative variable record patient : 1 . Surgery date 2 . Operation 3 . Manheim Peritonitis Score ( MPS ) 4 . Peritonitis classification ( a. fecal peritonitis b. purulent peritonitis , c. necrotizing Pancreatitis , d. postoperative peritonitis , e. necrotizing fasciitis ) 5 . Procedure relative comment 6 . Technical complication 7 . Duration surgery 8 . Difficulty operation ( 1=very difficult 5=very easy ) 9 . Peritoneal fluid culture 10 . Blood serum sample ( closure ) : ( WBC , Ht , Hb , SGOT , SGPT , LDH , Glu , Ure , Cre , K+ , Na+ , Ca2+ , Mg++ , TP , Alb , ALP , γ-GT , Amylase , Fibrinogen , PT , aPTT , INR , CRP , PCT , LBP ) 11 . Blood serum sample ( closure ) : IL 1α , IL 1β , IL6 , IL8 , IL12 , IL 10 , IL 18 , INF-γ , TNF-α , PGF-B , PAF , FGF-β , C5q , C3q , ICAM-I ( CD54 ) , spectalkine , CCL6 . 12 . Peritoneal sample ( closure ) : IL 1α , IL 1β , IL8 , IL12 , IL 10 , IL 18 , INF-γ , TNF-α , PGF-B , PAF , FGF-β , C5q , C3q , ICAM-I ( CD54 ) , spectalkine , CCL6 . 5.3 Admission Intensive Care Unit ( ICU ) 1 . SOFA Score 2 . APACHEII Score 3 . Blood serum sample : ( WBC , Ht , Hb , SGOT , SGPT , LDH , Glu , Ure , Cre , K+ , Na+ , Ca2+ , Mg++ , TP , Alb , ALP , γ-GT , Amylase , Fibrinogen , PT , aPTT , INR , CRP , PCT , LBP ) 5.4 Postoperative follow-up Follow-up evaluation perform every VAC dressing change hospitalize ICU laparostomy final closure patient decease . The following information record patient every change : 1 . Assessment peritoneal cavity 2 . Sofa score 3 . Peritoneal fluid culture 4. blood serum sample ( change ) : ( WBC , Ht , Hb , SGOT , SGPT , LDH , Glu , Ure , Cre , K+ , Na+ , Ca2+ , Mg++ , TP , Alb , ALP , γ-GT , Amylase , Fibrinogen , PT , aPTT , INR , CRP , PCT , LBP ) 5. blood serum sample ( change ) : IL 1α , IL 1β , IL6 , IL8 , IL12 , IL 10 , IL 18 , INF-γ , TNF-α , PGF-B , PAF , FGF-β , C5q , C3q , ICAM-I ( CD54 ) , spectalkine , CCL6 . 6 . Peritoneal sample ( change ) : IL 1α , IL 1β , IL6 , IL8 , IL12 , IL 10 , IL 18 , INF-γ , TNF-α , PGF-B , PAF , FGF-β , C5q , C3q , ICAM-I ( CD54 ) , spectalkine , CCL6 . 7 . Re- operation : 8 . Date re-operation : 9 . Re-procedure description : 10 . Date permanent abdominal wall closure : 11 . Successful primary abdominal closure : YES NO 12 . Type closure : 13 . Duration open abdomen : 14 . Number VAC dress change : 15 . Death : YES NO 16 . Date death : 17 . Duration ICU stay : 18 . Date ICU discharge : 19 . Duration hospitalization : 20 . Date discharge : 21 . Final patient outcome : 22 . Comments 5.5 Blood peritoneal fluid sample protocol Blood sample draw indwell arterial line ( 10ml ) every VAC dress change . Aspiration 5 ml peritoneal fluid Douglas space carry syringe prior lavage . Blood sample allow clot glass tube room temperature . Peritoneal sample collect glass tube . Both blood peritoneal sample centrifuge result serum store -70o processing . 5.6 Bacteriological sampling culture At initial explorative laparotomy aspiration 5 ml fluid Douglas space carry syringe . The sample empty rubber membrane-sealed sterile glass tube transport immediately laboratory , directly process . The process repeat change dressing . Moreover , every VAC dress change piece polyurethane sponge send microbiology department detection biofilm formation . 5.7 Antimicrobic prophylactic regime According Greek national guideline antimicrobic therapy , second generation cephalosporin ( 750 mg ) combine metronidazole ( 500 mg ) empirically use community acquire peritonitis , 30 minute prior induction anaesthesia . Against postoperative peritonitis , piperacillin-tazobactam ( 4.5 g ) employ . The antibiotic schema later adjust accord peritoneal fluid culture . 5.8 Control group Thirty patient without sepsis schedule major elective surgery constitute control group . Blood sample peritoneal fluid sample obtained end operation abdominal closure . Subsequently , blood sample obtain first third postoperative day serum plasma cytokine assessment . Inclusion criterion : 1 . Patient 18 year old 2 . Patient relatives sign date write informed consent form ( ICF ) indicate understand study procedure Exclusion criterion : 1 . Patient participate another clinical trial may affect study 's outcome 2 . Patients immune deficiency 3 . Documented seropositivity human immunodeficiency virus ( AIDS ) 4 . Patient receive steroid treatment medical condition 5 . Pre-existing parechymal liver disease ( Cirrhosis - Child-Pugh C ) 6 . Pregnancy 6.0 COMPLICATIONS AND ADVERSE EVENTS The coordinator require notify Ethics Committee accord regulation requirement . Serious Adverse Events include : 1 . Death regardless cause 2 . Any-life-threatening event 3 . Any re-hospitalization prolongation exist hospitalization 4 . Any event result persistent significant disability incapacity patient . 7.0 STATISTICAL ANALYSIS The objective study : ) ass peritoneal immune response patient severe intra-abdominal sepsis , b ) compare serum plasma cytokine value patient severe intra-abdominal sepsis correspond value peritoneal fluid c ) compare cytokine value serum plasma peritoneal fluid patient severe intra-abdominal sepsis patient without sepsis underwent major elective laparotomy . Statistical analysis include description pre-operative intraoperative postoperative outcome , indication patient characteristic associate outcomes . In order efficiently compare result patient severe intra-abdominal sepsis , control group without sepsis underwent major abdominal surgery employ ( Group A=sepsis Group B=elective surgery ) . Since study pre-specified hypothesis statistical analysis exploratory interpretation result within context . 8.0 DATA MONITORING PLAN The coordinator monitor data accrual . Furthermore , coordinator review progress clinical trial include safety data ensure possible conduct , record report accordance protocol , good clinical practice applicable regulatory requirement . 9.0 DATA CONFIDENTIALITY Each patient ill identify his/her initial unique patient identification number . Source data store source document . Only personnel responsible collect data transcribe case report form access data . Records remain site secure area . 10.0 FUNDING No additional funding execution present protocol necessary . The investigator willing execute present study without additional reimbursement . 11.0 ETHICS Prior study institution review board ( IRB ) approval obtain . Any change study protocol , informed consent form , investigator must re-approved IRB . All patient enrol study provide consent prior enter study . An informed consent form shall sign dated patient . The investigator retain form part study record . This study execute accordance Declaration Helsinki , agreement guideline conduct clinical investigation accordance principle ICH GCP outline E6 document . By sign present protocol , participant study commit carry accordance local legal requirement . 12.0 INFORMED CONSENT All eligible patient closest relative capacity provide inform consent . The described inclusion exclusion criterion design ensure entry appropriate population patient study approve local IRB . Screening criterion conduct coordinator . Eligible patient closest relative educate research proposal study investigator . To determine whether patient relative understood issue , he/she ask describe research entail whether question . All question address prior enrolment . The patient legal representative refuse participation study time . A write informed consent form generate . For patient , case report form ( CRF ) complete , provide general medical information history .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<criteria>1 . Patient &gt; 18 year old 2 . 30 patient severe abdominal sepsis order form study group 30 patient without sepsis undergo major elective surgery ( middle line incision &gt; 15cm ) form control group . 3 . Patient relatives sign date write informed consent form ( ICF ) indicate understand study procedure 1 . Patient 's Manheim Peritonitis Score &lt; 29 2 . Patient 's preoperative SOFA score &lt; 6 3 . The use temporary abdominal closure system 4 . Decease first VAC dress change 5 . Patient participate another clinical trial may affect study 's outcome 6 . Patients immune deficiency 7 . Documented seropositivity human immunodeficiency virus ( AIDS ) 8 . Patient receive steroid treatment medical condition 9 . Patient receive chronic antiinflammatory treatment 10 . Patient receive anti TNF treatment 11 . Preexisting parechymal liver disease ( Cirrhosis ChildPugh C ) 12 . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>VAC</keyword>
	<keyword>Severe abdominal sepsis</keyword>
	<keyword>Peritoneal immune reaction</keyword>
	<keyword>Peritonitis</keyword>
	<keyword>Immune peritoneal reaction abdominal sepsis treat VAC</keyword>
</DOC>